Capital Fund Management (CFM)’s Beam Therapeutics BEAM Stock Holding History

Capital Fund Management (CFM)’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-38,438	Closed	-$654K	–	2438
2025 Q2	$654K	Buy	+38,438	New	+$669K	﹤0.01%	2134
2024 Q4	–	Sell	-31,025	Closed	-$760K	–	2027
2024 Q3	$760K	Sell	31,025 -46,673	-60%	-$1.21M	﹤0.01%	1761
2024 Q2	$1.82M	Buy	77,698 +61,509	+380%	+$1.51M	0.01%	1423
2024 Q1	$535K	Buy	+16,189	New	+$504K	﹤0.01%	1851
2023 Q4	–	Sell	-14,117	Closed	-$340K	–	2103
2023 Q3	$340K	Buy	+14,117	New	+$378K	﹤0.01%	1849
2023 Q2	–	Sell	-26,942	Closed	-$825K	–	1676
2023 Q1	$825K	Sell	26,942 -41,000	-60%	-$1.62M	﹤0.01%	1327
2022 Q4	$2.66M	Buy	67,942 +40,546	+148%	+$1.82M	0.02%	838
2022 Q3	$1.31M	Sell	27,396 -2,813	-9%	-$160K	0.01%	1001
2022 Q2	$1.17M	Buy	30,209 +4,984	+20%	+$198K	0.01%	1016
2022 Q1	$1.45M	Buy	+25,225	New	+$1.65M	0.01%	1053

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Capital Fund Management (CFM)'s BEAM Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 38,438 shares — an estimated $654K sold.

Capital Fund Management (CFM) first reported a position in BEAM in Q1 2022 and held it in 10 quarters. The position peaked at $2.66M in Q4 2022. 219 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

Capital Fund Management (CFM) reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 38,438 Beam Therapeutics shares in Q3 2025, an estimated $654K.
Capital Fund Management (CFM) first reported a position in Beam Therapeutics in Q1 2022 and held it in 10 quarters.
Capital Fund Management (CFM)'s Beam Therapeutics position peaked at $2.66M in Q4 2022.
219 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.